With $1M in VC Cash, Ligon Discovery Gets Set to Commercialize Small-Molecule Microarrays

CEO Patrick Kleyn said this week that the Cambridge, Mass.-based startup is looking to partner with pharmaceutical and biotechnology companies that would like to use the firm's small-molecule microarrays, or SMMs, in their drug-discovery programs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.